Sen. Mark Kelly champions the PAIN Act to improve seniors' access to non-opioid pain treatments under Medicare.
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.
On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...
Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...
Chronic pain is complex and difficult to treat. Prescribing opioid pain medications has become controversial but may help ...
GlobalData on MSN8d
GLP-1RAs and opioid use disorder: a new frontier in addiction treatmentWhile medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...
On February 17, VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback